Avinger (AVGR) Shares are Down -20.26%

Avinger (AVGR) : During the past 4 weeks, traders have been relatively bearish on Avinger (AVGR), hence the stock is down -43.13% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -20.31% relative to the S&P 500. The 4-week change in the price of the stock is -42.54% and the stock has fallen -20.26% in the past 1 week.

The stock has recorded a 20-day Moving Average of 29.47% and the 50-Day Moving Average is 57.99%. Avinger (NASDAQ:AVGR): On Fridays trading session , Opening price of the stock was $3.8 with an intraday high of $3.82. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $3.55. However, the stock managed to close at $3.66, a loss of 2.40% for the day. On the previous day, the stock had closed at $3.75. The total traded volume of the day was 869,560 shares.


The company Insiders own 30.5% of Avinger shares according to the proxy statements. Institutional Investors own 45.48% of Avinger shares. During last six month period, the net percent change held by insiders has seen a change of -7.43%.

Avinger, Inc. is a commercial-stage medical device company. The Company designs, manufactures and sells image-guided, catheter-based systems that are used by physicians to treat patients with peripheral arterial disease (PAD). The Company focuses to introduce products based on its lumivascular platform, which is an intravascular image-guided system. The Company manufactures and sells a suite of products in the United States and select European markets. The Companys products include Lightbox imaging console, as well as Wildcat, Kittycat and the Ocelot family of catheters, which are designed to allow physicians to penetrate a total blockage in an artery, known as a chronic total occlusion (CTO). The Companys lumivascular platform offers real-time visualization of the inside of the artery during PAD treatment.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.